Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2016 May 6:6:25330.
doi: 10.1038/srep25330.

Rapid diagnosis of MDR and XDR tuberculosis with the MeltPro TB assay in China

Affiliations
Multicenter Study

Rapid diagnosis of MDR and XDR tuberculosis with the MeltPro TB assay in China

Yu Pang et al. Sci Rep. .

Abstract

New diagnostic methods have provided a promising solution for rapid and reliable detection of drug-resistant TB strains. The aim of this study was to evaluate the performance of the MeltPro TB assay in identifying multidrug-resistant (MDR-) and extensively drug-resistant tuberculosis (XDR-TB) patients from sputum samples. The MeltPro TB assay was evaluated using sputum samples from 2057 smear-positive TB patients. Phenotypic Mycobacterial Growth Indicator Tube (MGIT) 960 drug susceptibility testing served as a reference standard. The sensitivity of the MeltPro TB assay was 94.2% for detecting resistance to rifampicin and 84.9% for detecting resistance to isoniazid. For second-line drugs, the assay showed a sensitivity of 83.3% for ofloxacin resistance, 75.0% for amikacin resistance, and 63.5% for kanamycin resistance. However, there was a significant difference for detecting kanamycin resistance between the two pilot sites in sensitivity, which was 53.2% in Guangdong and 81.5% in Shandong (P = 0.015). Overall, the MeltPro TB assay demonstrated good performance for the detection of MDR- and XDR-TB, with a sensitivity of 86.7% and 71.4%, respectively. The MeltPro TB assay is an excellent alternative for the detection of MDR- and XDR-TB cases in China, with high accuracy, short testing turn-around time, and low unit price compared with other tests.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Flow diagram outlining patient enrollment and outcomes.

References

    1. Zumla A. et al. Drug-resistant tuberculosis–current dilemmas, unanswered questions, challenges, and priority needs. J Infect Dis. 205, Suppl 2, S228–240 (2012). - PubMed
    1. Pai M. & Schito M. Tuberculosis diagnostics in 2015: landscape, priorities, needs, and prospects. J Infect Dis 211, Suppl 2, S21–28 (2015). - PMC - PubMed
    1. World Health Oragnization. Global tuberculosis report 2014. World Health Organization, Geneva, Switherland. WHO/HTM/TB/2014.08 (2014).
    1. Wright A. et al. Epidemiology of antituberculosis drug resistance 2002–07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 373, 1861–1873 (2009). - PubMed
    1. Van Rie A. & Enarson D. XDR tuberculosis: an indicator of public-health negligence. Lancet 368, 1554–1556 (2006). - PubMed

Publication types

MeSH terms

LinkOut - more resources